Organogenesis Holdings (Organogenesis Holdings) Inventory-to-Revenue : 0.25 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Organogenesis Holdings Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Organogenesis Holdings's Average Total Inventories for the quarter that ended in Mar. 2024 was $28.0 Mil. Organogenesis Holdings's Revenue for the three months ended in Mar. 2024 was $110.0 Mil. Organogenesis Holdings's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.25.

Organogenesis Holdings's Inventory-to-Revenue for the quarter that ended in Mar. 2024 declined from Dec. 2023 (0.28) to Dec. 2023 (0.25)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Organogenesis Holdings's Days Inventory for the three months ended in Mar. 2024 was 88.95.

Inventory Turnover measures how fast the company turns over its inventory within a year. Organogenesis Holdings's Inventory Turnover for the quarter that ended in Mar. 2024 was 1.03.

Organogenesis Holdings Inventory-to-Revenue Historical Data

The historical data trend for Organogenesis Holdings's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organogenesis Holdings Inventory-to-Revenue Chart

Organogenesis Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory-to-Revenue

Get a 7-Day Free Trial

0.07

0.08

0.06

Organogenesis Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventory-to-Revenue	Get a 7-Day Free Trial															0.23	0.22	0.25	0.28	0.25

Competitive Comparison of Organogenesis Holdings's Inventory-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organogenesis Holdings's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Inventory-to-Revenue falls into.

Organogenesis Holdings Inventory-to-Revenue Calculation

Organogenesis Holdings's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (A: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )
=	( (24.783	+	28.253)	/	2 )	/	433.14
=	26.518					/	433.14
=	0.06

Organogenesis Holdings's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

	Inventory-to-Revenue (Q: Mar. 2024 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Dec. 2023 )	+	Total Inventories (Q: Mar. 2024 ))	/	count )	/	Revenue (Q: Mar. 2024 )
=	( (28.253	+	27.694)	/	2 )	/	109.976
=	27.9735					/	109.976
=	0.25

Organogenesis Holdings (NAS:ORGO) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Organogenesis Holdings's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	27.9735	/	28.696	*	365 / 4
	=	88.95

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Organogenesis Holdings's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	28.696	/	27.9735
	=	1.03

Organogenesis Holdings Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Organogenesis Holdings's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Organogenesis Holdings (Organogenesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organogenesis Holdings Inc (NAS:ORGO) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

2PQ:Germany

Address

85 Dan Road, Canton, MA, USA, 02021

Website

https://www.organogenesis.com

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.

Executives

Albert Erani	10 percent owner	150 DAN ROAD, 150 DAN ROAD, CANTON MA 01002
Michael W Katz	10 percent owner
Arthur S Leibowitz	director	139 SOUNDVIEW DRIVE, PORT WASHINGTON NY 11050
Michael Joseph Driscoll	director	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gary S. Gillheeney	director, officer: President and CEO	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gilberto Quintero	director	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Michele Ilene Korfin	director	17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Antonio S. Montecalvo	officer: VP Health Policy & Contracting	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Jon L Giacomin	director	7000 CARDINAL PLACE, DUBLIN OH 43017
David Francisco	officer: Chief Financial Officer	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Red Holdings, Llc	10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Prathyusha Duraibabu	director	C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND CA 94804
Glenn H Nussdorf	director, 10 percent owner
Alan A. Ades	director, 10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gn 2016 Organo 10-year Grat U/a/d September 30, 2016	10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021